Non classé

Welcome to our new recruits !

Welcome to our new recruits ! 887 586 MCE CARREL

Alexandra CARREL, Jeremy PAPPALARDO and the MCE CARREL Team are pleased to welcome two new colleagues who bring a wealth of experience to the firm :

Anne-Caroline BERAUD

Anne-Caroline joined MCE Carrel in February 2022, after three years as legal counsel (contract law) in a biotech company in clinical phase. She assisted clinical and R&D teams in the drafting and negotiation of their clinical trial agreements, collaboration and research service agreements. Anne-Caroline has specialized in health law since she started her career in a life science technology transfer company, a public-private sector in which she worked for four years.


Armand joined the firm in April 2022 after more than 11 years as a contract & IP lawyer for a SATT and a national innovation research institute. Specialized in health and pharmaceutical law, NTIC and electronics, Armand has notably accompanied innovative projects from academic laboratories to the market, drafting and negotiating contracts in French and English. His training in international and European law is immensely relevant.

We wish a very warm welcome to both Anne-Caroline and Armand.

Microbiome Innovation Strategic Partnership – GNUBIOTICS & ADM

Microbiome Innovation Strategic Partnership – GNUBIOTICS & ADM 480 320 MCE CARREL

MCE CARREL is pleased to have assisted GNUBIOTICS in its negotation with ADM on their Strategic Partnership in Microbiome Innovation.

For the full story : GNUBIOTICS Press release

Jeremy Pappalardo

MCE CARREL has a new partner !

MCE CARREL has a new partner ! 598 900 MCE CARREL

MCE CARREL Avocats is very pleased to announce the promotion of Jeremy PAPPALARDO to partner of the firm as of January 1, 2022, alongside Alexandra CARREL. The whole team congratulates him on his appointment and wishes him every success.

A member of the firm since 2017, Jeremy specialises in Life Sciences Innovation and Digital. His clients include research institutes, SATTs, e-health start-ups and biotech companies. Jeremy’s promotion is a new milestone in the development of MCE CARREL, to which he has continuously contributed since its creation.


MCE CARREL & SEMIA – Licensing Master Class

MCE CARREL & SEMIA – Licensing Master Class 1000 667 MCE CARREL

19th MAY 2021

Alexandra CARREL and Jeremy PAPPALARDO  are leading a workshop on Term Sheet negotiation in conjunction with the Strasbourg-baesd incubator, SEMIA. The workshop will take place via web-conference, on Wednesday, 19th May in the morning.

Term Sheet negotiation:

  • Case presentation
  • Groupwork
  • Feedback & conclusion



Cabinet Carrel assisted VECT-HORUS S.A.S. (Marseille, France) in the negotiation of a collaboration and licensing agreement with ONO Pharmaceutical Co. (Osaka, Japan)




Vect-Horus S.A.S. (Marseille, France) announced today that Vect-Horus and Ono Pharmaceutical Co., Ltd. (Osaka, Japan) signed a collaboration and license agreement, focused on the development of novel molecules targeting neurodegenerative diseases.

Under the agreement, Vect-Horus will receive research fees, success-based milestones on the research and development progress, as well as royalties on sales of the products.

Vect-Horus will apply its proprietary VECTrans® technology, which facilitates the transport of drugs into the brain, to ONO’s therapeutic molecules. Vect-Horus will utilize its expertise to conjugate these therapeutic molecules with its peptide vectors and demonstrate improved brain uptake and efficacy in animals. Ono will have worldwide exclusive rights to develop and commercialize any pharmaceutical products arising out of the drug discovery collaboration.

“We are delighted to partner with Ono, one of the oldest pharmaceutical companies in the world and an important developer of innovative drugs,” commented Alexandre Tokay, Chief Executive Officer and cofounder of Vect-Horus. “Our agreement with Ono strengthens our long-standing commitment to improve, using our technology, the brain delivery of therapeutic molecules and bring forward novel therapies that address critical unmet needs.”

About Vect-Horus Vect-Horus designs and develops vectors that facilitate targeting and delivery of therapeutic or imaging agents to organs, including the brain and tumors. Vect-Horus combines these different agents to its vectors that specifically target various receptors, allowing these agents to cross natural barriers (including the blood-brain-barrier) which limit access of therapeutic or imaging agents to their targets. The proof of concept of the technology has already been established in animal models using different vectorized molecules. Created in 2005, Vect-Horus is a spin-off of the Institute for Neurophysiopathology (INP, UMR7051, CNRS and Aix Marseille University), headed by Dr Michel Khrestchatisky, co-founder. To learn more about Vect-Horus, visit For more information about this press release, please contact Elodie Dormes, Business Development Manager of Vect-Horus: